Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.

Identifieur interne : 004717 ( Ncbi/Curation ); précédent : 004716; suivant : 004718

L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.

Auteurs : J. Opacka-Juffry [Royaume-Uni] ; D J Brooks

Source :

RBID : pubmed:7651438

English descriptors

Abstract

Recent experimental reports concerning L-dihydroxyphenylalanine (L-DOPA) and aromatic L-amino acid decarboxylase (AADC, L-DOPA decarboxylase) are reviewed in this article. Both in vitro and in vivo data now suggest that L-DOPA is an endogenous neuroactive compound that is released from neurons and acts as a neurotransmitter or neuromodulator in the brain. Administration of exogenous L-DOPA affects dopamine receptor status, AADC activity, and mitochondrial oxidation in experimental animals. The type and severity of these effects depend on the duration of the treatment. These findings may partly explain the limited efficacy of L-DOPA therapy in Parkinson's disease (PD). AADC also plays a controlling role in the central nervous system, being a regulatory enzyme in the synthesis of a putative neuromodulator 2-phenylethylamine and other trace amines. Recent experimental findings on AADC activity and localisation are of importance because they suggest that striatal [18F]DOPA uptake used as an indicator of PD progression in positron emission tomography (PET) studies is likely to overestimate nigrostriatal integrity in advanced PD. Possible new PET tracers of presynaptic dopaminergic function are discussed in this context.

DOI: 10.1002/mds.870100302
PubMed: 7651438

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:7651438

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.</title>
<author>
<name sortKey="Opacka Juffry, J" sort="Opacka Juffry, J" uniqKey="Opacka Juffry J" first="J" last="Opacka-Juffry">J. Opacka-Juffry</name>
<affiliation wicri:level="2">
<nlm:affiliation>MRC Cyclotron Unit, Hammersmith Hospital, London, England.</nlm:affiliation>
<country>Royaume-Uni</country>
<placeName>
<region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Cyclotron Unit, Hammersmith Hospital, London</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D J" last="Brooks">D J Brooks</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1995">1995</date>
<idno type="RBID">pubmed:7651438</idno>
<idno type="pmid">7651438</idno>
<idno type="doi">10.1002/mds.870100302</idno>
<idno type="wicri:Area/PubMed/Corpus">004995</idno>
<idno type="wicri:Area/PubMed/Curation">004995</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004965</idno>
<idno type="wicri:Area/Ncbi/Merge">004717</idno>
<idno type="wicri:Area/Ncbi/Curation">004717</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.</title>
<author>
<name sortKey="Opacka Juffry, J" sort="Opacka Juffry, J" uniqKey="Opacka Juffry J" first="J" last="Opacka-Juffry">J. Opacka-Juffry</name>
<affiliation wicri:level="2">
<nlm:affiliation>MRC Cyclotron Unit, Hammersmith Hospital, London, England.</nlm:affiliation>
<country>Royaume-Uni</country>
<placeName>
<region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Cyclotron Unit, Hammersmith Hospital, London</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D J" last="Brooks">D J Brooks</name>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="1995" type="published">1995</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Brain (physiopathology)</term>
<term>Brain Mapping</term>
<term>Corpus Striatum (physiology)</term>
<term>Dihydroxyphenylalanine (physiology)</term>
<term>Dopa Decarboxylase (physiology)</term>
<term>Dopamine (physiology)</term>
<term>Humans</term>
<term>Neurotransmitter Agents (physiology)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Synaptic Transmission (physiology)</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en">
<term>Dihydroxyphenylalanine</term>
<term>Dopa Decarboxylase</term>
<term>Dopamine</term>
<term>Neurotransmitter Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Corpus Striatum</term>
<term>Synaptic Transmission</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Brain</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Brain Mapping</term>
<term>Humans</term>
<term>Tomography, Emission-Computed</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Recent experimental reports concerning L-dihydroxyphenylalanine (L-DOPA) and aromatic L-amino acid decarboxylase (AADC, L-DOPA decarboxylase) are reviewed in this article. Both in vitro and in vivo data now suggest that L-DOPA is an endogenous neuroactive compound that is released from neurons and acts as a neurotransmitter or neuromodulator in the brain. Administration of exogenous L-DOPA affects dopamine receptor status, AADC activity, and mitochondrial oxidation in experimental animals. The type and severity of these effects depend on the duration of the treatment. These findings may partly explain the limited efficacy of L-DOPA therapy in Parkinson's disease (PD). AADC also plays a controlling role in the central nervous system, being a regulatory enzyme in the synthesis of a putative neuromodulator 2-phenylethylamine and other trace amines. Recent experimental findings on AADC activity and localisation are of importance because they suggest that striatal [18F]DOPA uptake used as an indicator of PD progression in positron emission tomography (PET) studies is likely to overestimate nigrostriatal integrity in advanced PD. Possible new PET tracers of presynaptic dopaminergic function are discussed in this context.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004717 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 004717 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:7651438
   |texte=   L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:7651438" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024